RT Book, Section
A1 Vanderah, Todd W.
A2 Katzung, Bertram G.
A2 Vanderah, Todd W.
SR Print(0)
ID 1176979831
T1 Cannabinoid Drugs
T2 Basic & Clinical Pharmacology, 15e
YR 2021
FD 2021
PB McGraw-Hill
PP New York, NY
SN 9781260452310
LK accessmedicine.mhmedical.com/content.aspx?aid=1176979831
RD 2024/04/25
AB CASE  STUDYA  42-year-old  woman  with  metastatic  breast  cancer  being  treated  with  a  combination  of  cyclophosphamide,  doxorubicin,  and  fluorouracil  (5-FU)  complains  of  pain  due  to  chemotherapy-induced  peripheral  neuropathy.  She  has  been  unwilling  to  eat  due  to  nausea  and  vomiting  induced  by  her  medications.  She  is  receiving  heavy  doses  of  oxycodone  for  pain,  but  this  has  resulted  in  severe  constipation.  Upon  her  visit  with  the  oncologist  she  shows  physical  signs  of  cachexia  and  reports  ongoing  pain  in  her  back  and  hips.  Friends  suggest  medical  marijuana  as  a  strategy  for  controlling  her  present  symptoms.  What  evidence  supports  this  approach?  What  might  be  the  unwanted  effects  of  this  strategy?